Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin's lymphoma not eligible for intensive chemotherapy.

MLA

Abdayem, Pamela, et al. “Attenuated Cytarabine, Etoposide, Dexamethasone plus Rituximab (R‐Mini‐CYVE) Regimen for Patients with Relapsed or Refractory B‐cell Non–Hodgkin’s Lymphoma Not Eligible for Intensive Chemotherapy.” European Journal of Haematology, vol. 106, no. 4, Apr. 2021, pp. 574–83. EBSCOhost, https://doi.org/10.1111/ejh.13589.

APA

Abdayem, P., Ibrahim, N., El Dakdouki, Y., Willekens, C., Ghez, D., A. Rouche, J., Dartigues, P., Desmaris, R., Danu, A., Rossignol, J., Lazarovici, J., Fermé, C., Ribrag, V., & Michot, J. M. (2021). Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy. European Journal of Haematology, 106(4), 574–583. https://doi.org/10.1111/ejh.13589

Chicago

Abdayem, Pamela, Nathalie Ibrahim, Yolla El Dakdouki, Christophe Willekens, David Ghez, Julia A. Rouche, Peggy Dartigues, et al. 2021. “Attenuated Cytarabine, Etoposide, Dexamethasone plus Rituximab (R‐Mini‐CYVE) Regimen for Patients with Relapsed or Refractory B‐cell Non–Hodgkin’s Lymphoma Not Eligible for Intensive Chemotherapy.” European Journal of Haematology 106 (4): 574–83. doi:10.1111/ejh.13589.